Observational Study for the Identification of Fatigue and Gait Biomarkers in Populations With Neuromuscular Pathologies in the Clinical Context and Daily Life
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Muscular Dystrophies
- Sponsor
- IRCCS Eugenio Medea
- Enrollment
- 120
- Locations
- 2
- Primary Endpoint
- Variation in walking speed during a 6-minutes walking test
- Status
- Recruiting
- Last Updated
- 3 months ago
Overview
Brief Summary
This study has the general objective of observing walking parameters during a clinical test to objectively estimate fatigue in patients with neuromuscular diseases. Furthermore, the investigators want to evaluate the feasibility of collecting physical activity in daily life conditions during a one-week monitoring period using a wearable sensor.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Ambulant adult patients with genetic diagnosis of muscular dystrophy/myopathy (dystrophinopathies, muscular dystrophies and congenital and non-congenital myopathies), of spinal muscular atrophy (SMA) and with molecular diagnosis of Charcot-Marie Tooth 1 or
- •independent walking, even with assistance;
Exclusion Criteria
- •Dilated or ischemic heart disease with moderate impairment;
- •Chronic respiratory failure: forced vital capacity (FVC) \< 40%; more than 5% of nocturnal time spent with peripheral oxygen saturation levels \< 90.
Outcomes
Primary Outcomes
Variation in walking speed during a 6-minutes walking test
Time Frame: Baseline
Variation in walking speed calculated as difference between the first and the final minute of the a 6-minutes walking test
Subjective fatigue
Time Frame: Baseline
Evaluation of subjective fatigue using the Fatigue Severity Scale (FSS). The minimum value is 0, the maximum is 63. Higher scores mean worse outcome.
Secondary Outcomes
- Clinical progression of the neuromuscular disease(Baseline)
- Variation in gait variability during the 6-Minutes Walking Test(Baseline)